Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients

Neurological Research

Volumn 28, Issue 3, 2006, Pages 262-269

  Zivadinov, Robert ^a,b,e   Nasuelli, Davide ^b   Tommasi, Maria Antonietta ^b   Serafin, Maurizia ^c   Bratina, Alessio ^b   Ukmar, Maja ^b   Pirko, Istvan ^d   Johnson, Aaron J ^d   Furlan, Christina ^b   Pozzi Mucelli, Roberto S ^b   Monti Bragadin, Luisa ^b   Grop, Attilio ^b   Zambon, Massimo ^b   Antonello, Rodolfo M ^b   Cazzato, Giuseppe ^b   Zorzon, Marino ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Cytomegalovirus; Disease severity; Immune evasion; Immunomodulation; MRI; Multiple sclerosis

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN G; MEASLES ANTIBODY; RUBELLA ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMAGE ANALYSIS; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEASLES VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RECURRENCE RISK; RUBELLA VIRUS; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; CYTOMEGALOVIRUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; RANDOM ALLOCATION; REGRESSION ANALYSIS;

EID: 33646816323     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X98134     Document Type: Article

References (44)

1. Atkins GJ, McQuaid S, Morris-Downes MM, et al. Transient virus infection and multiple sclerosis. Rev Med Virol 2000; 10: 291-303
2. Cermelli C, Jacobson S. Viruses and multiple sclerosis. Viral Immunol 2000; 13: 255-267
3. Dalgleish AG. Viruses and multiple sclerosis. Acta Neurol Scand Suppl 1997; 169: 8-15
4. Derfuss T, Gurkov R, Then Bergh F, et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 2001; 124: 1325-1335
5. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-766
6. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60-63
7. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-1288
8. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995; 45: 478-482
9. Lucchinetti CF, Bruck W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-274
10. Tumani H, Tourtellotte WW, Peter JB, et al. Acute optic neuritis: Combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group. J Neurol Sci 1998; 155: 44-49
11. Frederiksen JL, Sindic CJ. Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI. Mult Scler 1998; 4: 22-26
12. Edwards S, Zvartau M, Clarke H, et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 736-741
13. Michielsens B, Wilms G, Marchal G, et al. Serial magnetic resonance imaging studies with paramagnetic contrast medium: Assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol 1990; 30: 258-259
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
16. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683-638
17. Grimaud J, Lai M, Thorpe J, et al. Quantification of MRI lesion load in multiple sclerosis: A comparison of three computer-assisted techniques. Magn Reson Imaging 1996; 14: 495-505
18. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-1247
19. Zivadinov R, De Masi R, Nasuelli D, et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology 2001; 43: 272-278
20. Myhr KM, Riise T, Barrett-Connor E, et al. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: A population based case-control study from western Norway. J Neurol Neurosurg Psychiatry 1998; 64: 539-542
21. Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55: 178-184
22. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-1428
23. Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis: Clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168: 96-106
24. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-1315
25. Compston DA, Vakarelis BN, Paul E, et al. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986; 109: 325-344
26. Sumaya CV, Myers LW, Ellison GW, et al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985; 17: 371-377
27. Felgenhauer K, Schadlich HJ, Nekic M, et al. Cerebrospinal fluid virus antibodies. A diagnostic indicator for multiple sclerosis? J Neurol Sci 1985; 71: 291-299
28. Saha K, Zhang J, Gupta A, et al. Isolation of primary HIV-1 that target CD8+ T lymphocytes using CD8 as a receptor. Nat Med 2001; 7: 65-72
29. Kano Y, Shiohara T. Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci 2000; 22: 196-204
30. Sweet C. The pathogenicity of cytomegalovirus. FEMS Microbiol Rev 1999; 23: 457-482
31. Mocarski ES, Jr. Immunomodulation by cytomegaloviruses: Manipulative strategies beyond evasion. Trends Microbiol 2002; 10: 332-339
32. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3607-3609
33. Jarvis MA, Nelson JA. Human cytomegalovirus persistence and latency in endothelial cells and macrophages. Curr Opin Microbiol 2002; 5: 403-407
34. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 1993; 151: 4455-4464
35. Heise MT, Pollock JL, O'Guin A, et al. Murine cytomegalovirus infection inhibits IFN gamma-induced MHC class II expression on macrophages: The role of type I interferon. Virology 1998; 241: 331-344
36. Wang EC, Taylor-Wiedeman J, Perera P, et al. Subsets of CD8+, CD57+ cells in normal, healthy individuals: Correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses. Clin Exp Immunol 1993; 94: 297-305
37. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-472
38. Percivalle E, Revello MG, Vago L, et al. Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. J Clin Invest 1993; 92: 663-670
39. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705
40. Sedmak DD, Chaiwiriyakul S, Knight DA, et al. The role of interferon beta in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells. Arch Virol 1995; 140: 111-126
41. Benedict CA, Banks TA, Senderowicz L, et al. Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus detente. Immunity 2001; 15: 617-626
42. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45: 1277-1285
43. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504
44. Ho M. Pathology of cytomegalovirus infection in man. In: Greenough WB, Merigan TC, eds. Cytomegalovirus, biology and infection: Current topics in infectious disease, New York, NY: Plenum Press, 1982: pp. 171-204